Highlights

  • ResMed reported double-digit Revenue growth and Margin expansion in its latest quarterly results.
  • Growing awareness around sleep apnea and obesity-linked health conditions continues to support long-term industry Demand.
  • The company is expanding its digital health ecosystem, Manufacturing footprint, and Shareholder returns strategy.

Healthcare technology company ResMed (ASX:RMD) has remained firmly on investor watchlists as the global conversation around sleep health, obesity treatment, digital healthcare, and home-based care continues to accelerate. While market sentiment around sleep apnea treatment companies faced pressure over the past year amid concerns surrounding weight-loss drugs, recent operational performance and industry developments have shifted the narrative toward long-term opportunity rather than disruption.

The company, known globally for its sleep apnea devices, masks, cloud-connected platforms, and digital health technologies, operates across more than 140 countries and has built a significant presence in the growing home healthcare ecosystem. As healthcare systems increasingly prioritise remote monitoring, preventive care, and AI-powered health management, companies operating in connected care environments are receiving renewed investor focus.

Importantly, ResMed’s broader Business story now extends well beyond traditional CPAP machines. The company has steadily expanded into software-driven healthcare solutions, patient monitoring systems, residential care software, and cloud-based data management platforms that help providers manage patient outcomes more efficiently.

This broader Diversification has become increasingly relevant in a healthcare environment where ageing populations, rising chronic disease prevalence, and growing pressure on hospital systems are driving demand for care outside traditional clinical settings.

The Debate Around GLP-1 Drugs and Sleep Apnea

One of the biggest themes surrounding ResMed over the past year has been the emergence of GLP-1 obesity drugs and the potential implications for sleep apnea treatment demand.

As weight-loss therapies gained widespread attention globally, investors questioned whether fewer obesity-related sleep apnea cases could eventually reduce demand for CPAP therapy and related respiratory care products. Since obesity is strongly associated with obstructive sleep apnea, the market initially viewed the rise of these therapies as a possible structural challenge for sleep-device manufacturers.

However, over time, the discussion has become more nuanced.

Rather than replacing sleep apnea treatment entirely, healthcare providers and researchers increasingly appear to be viewing weight management therapies and sleep treatment solutions as complementary components of broader chronic disease management.

For many patients, sleep apnea remains underdiagnosed for years. Greater interaction with healthcare systems through obesity treatment programs may actually increase screening rates for sleep disorders and respiratory health conditions. This creates the possibility that more patients enter the sleep-care ecosystem rather than fewer.

ResMed management has highlighted this evolving trend through patient data analysis that suggests individuals using both PAP therapy and GLP-1 treatments may maintain strong adherence to sleep treatment programs. The company believes increasing health awareness, wearable health technology adoption, and greater physician engagement could help drive diagnosis rates higher over time.

That argument has become increasingly important because sleep apnea remains significantly underdiagnosed globally despite its connection to broader health risks including cardiovascular disease, fatigue, metabolic disorders, and cognitive decline.

As public awareness around sleep quality and chronic disease prevention grows, sleep health is increasingly being viewed as a mainstream healthcare priority rather than a niche category.

Strong Financial Performance Reinforces Operational Momentum

ResMed’s latest quarterly results also contributed to the renewed attention around the company’s Long-term Growth trajectory.

For the third quarter of fiscal year 2026, the company reported revenue growth of 11% year-on-year to approximately US$1.4 billion, while constant currency growth reached 8%. Gross margins expanded significantly, reflecting manufacturing efficiencies, component cost improvements, and operational discipline.

The company also delivered strong Earnings growth during the quarter, with Operating Income, Net Income, and Earnings Per Share all improving compared to the prior corresponding period.

Importantly, growth was broad-based across multiple regions and product categories.

Revenue from devices, masks, and accessories continued to rise across the Americas, Europe, Asia, and other international markets. The company’s Residential Care Software segment also continued to expand, reinforcing management’s strategy of building a more diversified digital health platform.

Margin performance was another key focus for investors. Gross margin expansion reflected improvements in logistics efficiencies and manufacturing operations following the broader Supply chain disruptions that impacted the global healthcare equipment sector in prior years.

At the same time, ResMed continued investing heavily in Research and Development, Marketing, technology infrastructure, and digital health initiatives designed to support long-term growth.

The company’s Operating Cash Flow remained robust, allowing management to continue balancing business Investment with shareholder returns through dividends and share repurchases.

Digital Health and AI-Powered Care Becoming Central Themes

One of the more important long-term themes supporting ResMed’s growth outlook is the increasing integration of digital technology into healthcare delivery.

Healthcare systems globally are moving toward connected care ecosystems where patient monitoring, compliance tracking, remote diagnostics, and AI-assisted treatment management become more central to everyday healthcare operations.

ResMed has spent years building cloud-connected platforms capable of collecting and analysing large volumes of sleep and breathing health data. Its software systems support healthcare providers, caregivers, and residential care operators by improving patient monitoring and operational efficiency.

The company now manages billions of nights of sleep-related health data through its connected ecosystem, giving it access to valuable real-world patient insights.

This data-driven healthcare model is becoming increasingly relevant as governments and insurers seek ways to reduce hospital admissions, improve chronic disease management, and shift more care into home settings.

The rise of AI-powered healthcare tools may further strengthen the competitive position of companies already operating large-scale connected health ecosystems.

For investors, this means ResMed is increasingly being assessed not only as a medical device company, but also as a digital healthcare platform with recurring software revenue opportunities and data-driven growth potential.

That broader technology positioning may become increasingly important as healthcare companies compete on ecosystem strength, integration capabilities, and long-term patient engagement.

Expansion Initiatives Reflect Long-Term Confidence

ResMed has also continued investing in operational expansion initiatives that signal management’s confidence in future demand trends.

Among the notable developments announced recently was the expansion of the company’s U.S. distribution footprint through a new Facility in Indiana expected to strengthen logistics capacity across North America.

The company has also continued rolling out new mask products and expanding product availability across international markets.

Product innovation remains a critical competitive Factor in sleep health, where patient comfort, adherence rates, usability, and digital integration all influence long-term adoption.

New mask technologies and improved comfort-focused designs can play an important role in increasing treatment compliance, particularly for patients beginning PAP therapy for the first time.

At the same time, ResMed’s continued investment in software integration and digital monitoring tools reflects the healthcare industry’s broader shift toward connected patient experiences.

The company’s Acquisition strategy and portfolio review activities also indicate ongoing interest in strengthening its healthcare technology ecosystem over the long term.

Broader Healthcare Trends Continue Supporting the Industry

Beyond company-specific developments, several structural healthcare trends continue supporting long-term demand for sleep and respiratory care services globally.

Population ageing remains one of the most significant drivers. Older populations generally experience higher rates of chronic respiratory conditions, sleep disorders, cardiovascular disease, and home healthcare needs.

Obesity rates also continue rising across many developed and emerging markets, increasing the prevalence of sleep apnea and related respiratory complications.

At the same time, healthcare systems are increasingly focused on preventive care and chronic disease management rather than reactive treatment alone.

Sleep quality is now more widely recognised as an important contributor to overall health outcomes, productivity, cardiovascular wellness, and cognitive performance. This shift in awareness has gradually expanded the addressable market for sleep-related healthcare solutions.

The rise of wearable health devices and consumer health tracking technologies is also encouraging more individuals to seek diagnosis and treatment for sleep-related conditions.

Healthcare digitisation trends further support companies operating cloud-based healthcare ecosystems. Remote patient monitoring, telehealth integration, and AI-assisted care management are expected to remain major themes across the healthcare sector for years ahead.

As a result, companies with established digital health infrastructure may continue benefiting from broader healthcare transformation trends.

Share Price Performance

Shares of ASX:RMD closed at AUD 29.25 on 26 May 2026, rising 0.83% during the session.

Despite the latest daily gain, the stock remains lower over both the past month and the past year, reflecting the broader Volatility that impacted healthcare technology and sleep-health related stocks amid changing market expectations around obesity treatments and healthcare sector growth trends.

Over the past 12 months, investor sentiment toward sleep apnea treatment providers has fluctuated considerably as markets attempted to assess the long-term impact of GLP-1 therapies on sleep-related healthcare demand.

However, the company’s recent financial performance, operational growth, and expanding digital healthcare positioning have helped keep the stock actively discussed among both institutional and retail investors.

With a Market Capitalisation exceeding AUD 42 billion, ResMed remains one of the larger healthcare technology names listed on the ASX and continues to attract attention due to its exposure to long-term healthcare megatrends.

Investor Focus Shifting Toward Long-Term Healthcare Demand

The broader market conversation around ResMed increasingly appears to be evolving away from short-term disruption fears and toward long-term structural healthcare demand.

Investors are now paying closer attention to several larger themes:

  • Rising awareness of sleep-related health conditions
  • Growth in home-based healthcare delivery
  • AI-enabled healthcare ecosystems
  • Digital patient monitoring expansion
  • Increasing chronic disease management needs
  • Global healthcare infrastructure modernisation

These trends extend well beyond any single product category and position companies operating integrated healthcare technology ecosystems in a potentially favourable long-term environment.

ResMed’s combination of hardware, recurring consumable products, software services, patient monitoring systems, and global healthcare reach provides exposure to multiple healthcare growth drivers simultaneously.

While competitive risks, regulatory developments, and changing reimbursement environments remain important considerations for investors, the company’s ability to continue growing revenue, expanding margins, and investing in innovation has reinforced confidence in its broader operating model.

Conclusion

ResMed continues to sit at the intersection of several major global healthcare trends including sleep health awareness, chronic disease management, home-based care, digital health integration, and AI-powered healthcare technology.

Although investor concerns around obesity drugs created considerable uncertainty across the sleep apnea treatment space, recent industry developments and company performance suggest the long-term demand outlook may be more resilient than initially feared.

The company’s latest quarterly performance demonstrated continued revenue growth, improving profitability, strong cash generation, and expanding global operations. At the same time, its growing software ecosystem and connected healthcare infrastructure position it within one of the fastest-evolving areas of the healthcare sector.

As healthcare systems increasingly prioritise preventive care, remote monitoring, and patient-centric digital solutions, companies with established healthcare technology ecosystems may remain firmly on investor radars.

For Market Participants monitoring large-cap healthcare opportunities on the ASX, ResMed remains a company closely tied to the future direction of sleep health, respiratory care, and connected healthcare delivery worldwide.